Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 30,991 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Healthy
Interventions
asimadoline
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 56 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Healthy
Interventions
Mind-Body Medicine Training Program
Other
Lead sponsor
The Center for Mind-Body Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Parkinson Disease
Interventions
Droxidopa, Carbidopa
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions
encorafenib, Binimetinib, Cetuximab
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
New York, New York • Germantown, Tennessee
Conditions
Pleural Effusion
Interventions
Manometry-guided thoracentesis, Symptom-guided thoracentesis
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Renal Cell Carcinoma
Interventions
quinacrine
Drug
Lead sponsor
Cleveland BioLabs
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Albany, New York • Charlotte, North Carolina
Conditions
Sarcoma
Interventions
cilengitide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
3
States / cities
La Jolla, California • San Francisco, California • Nashville, Tennessee
Conditions
Self-Injurious Behavior, Suicidal Ideation, Suicide Attempts
Interventions
Therapeutic Evaluative Conditioning, Neutral comparison condition
Behavioral
Lead sponsor
Franciscan Hospital For Children, INC.
Other
Eligibility
12 Years to 19 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Brighton, Massachusetts
Conditions
Anxiety
Interventions
Self-Administered, Active Cognitive Bias Modification (CBM), Self-Administered, minimally effective attention-control version of the CBM program
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
12 Years to 17 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Gemcitabine Hydrochloride, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Heptocellular Cancer
Interventions
Transarterial Radioembolization, Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee

NCT00854295
Conditions
Osteoarthritis, Traumatic Arthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus, Valgus, Flexion Deformities
Interventions
NexGen LPS-Flex Mobile Bearing Knee
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
Not listed
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
3
States / cities
Tamarac, Florida • Auburn Hills, Michigan • Knoxville, Tennessee
Conditions
Class IV Angina
Interventions
Not listed
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Nashville, Tennessee
Conditions
Lymphatic Malformation
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
6 Months to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 8 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluating Neuromuscular Stimulation for Restoring Hand Movements

NCT03385005
Conditions
Healthy Volunteers, Spinal Cord Injury Cervical, Physical and Rehabilitation Medicine
Interventions
Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
AMG386 plus PLD, Placebo plus PLD
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 18 more
Completed Not applicable Interventional Results available

Prospective Study of Thoracolumbar Spinal Fusion Graft

NCT02297256
Conditions
Lumbar Degenerative Disc Disease
Interventions
BMAC & Allograft, Iliac Crest Bone Graft
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
3
States / cities
New York, New York • Westbury, New York
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 formulation 3, RSVPreF3 formulation 2, Boostrix-ex-US, Boostrix-US, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Rochester, New York + 1 more
Conditions
Breast Cancer, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Radiotherapy Side Effect, Radiation Burn, Radiation Dermatitis, Radiotherapy; Complications
Interventions
Mepitel Film®
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Clairton, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Conditions
Wrinkle
Interventions
Tixel
Device
Lead sponsor
Eric Bernstein, MD
Other
Eligibility
25 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison Study of Lay Person Finger Stick Versus Blood Draw

NCT01913145
Conditions
Diabetes
Interventions
A1c, Self-collection, Blood sample
Device
Lead sponsor
Home Access Health Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
San Mateo, California • Louisville, Kentucky
Conditions
Breast Cancer
Interventions
Axillary lymph node dissection (ALND), Axillary radiotherapy (ART)
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
3
States / cities
Bethesda, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania
Conditions
Urinary Bladder Cancer, Muscle-invasive
Interventions
Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more